143 related articles for article (PubMed ID: 23914751)
1. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
Aagaard L; Hansen EH
Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Warrer P; Aagaard L; Hansen EH
Drug Saf; 2014 Oct; 37(10):805-13. PubMed ID: 25112669
[TBL] [Abstract][Full Text] [Related]
3. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.
Eriksson R; Aagaard L; Jensen LJ; Borisova L; Hørlück D; Brunak S; Hansen EH
Pharmacol Res Perspect; 2014 Jun; 2(3):e00038. PubMed ID: 25505588
[TBL] [Abstract][Full Text] [Related]
4. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
Gahr M; Connemann BJ; Schönfeldt-Lecuona C; Zeiss R
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067776
[TBL] [Abstract][Full Text] [Related]
7. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
Cornelius VR; Liu K; Peacock J; Sauzet O
BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
[TBL] [Abstract][Full Text] [Related]
8. [Life-threatening heart failure caused by ADHD medication. Five case reports described].
Wikström G; Kvidal P; Hagström E
Lakartidningen; 2012 Nov 7-13; 109(45):2016-8. PubMed ID: 23240309
[No Abstract] [Full Text] [Related]
9. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
[TBL] [Abstract][Full Text] [Related]
10. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
Tobaiqy M; Stewart D; Helms PJ; Williams J; Crum J; Steer C; McLay J
Drug Saf; 2011 Mar; 34(3):211-9. PubMed ID: 21332245
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
12. Food and Drug Administration monitoring of adverse drug reactions.
Sills JM; Tanner LA; Milstien JB
Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
[TBL] [Abstract][Full Text] [Related]
13. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
14. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies.
Aagaard L; Hansen EH
Neuropsychiatr Dis Treat; 2011; 7():729-44. PubMed ID: 22247615
[TBL] [Abstract][Full Text] [Related]
15. Structures and processes in spontaneous ADR reporting systems: a comparative study of Australia and Denmark.
Aagaard L; Stenver DI; Hansen EH
Pharm World Sci; 2008 Oct; 30(5):563-70. PubMed ID: 18350372
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
17. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers.
Vansickel AR; Fillmorex MT; Hays LR; Rush CR
Am J Drug Alcohol Abuse; 2008; 34(3):293-305. PubMed ID: 18428072
[TBL] [Abstract][Full Text] [Related]
18. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
19. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
Kesselheim AS; Franklin JM; Avorn J; Duke JD
BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
